Penbrook Management’s Harvard Bioscience HBIO Stock Holding History

Penbrook Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,000	Closed	-$180K	–	100
2022 Q2	$180K	Hold	5,000	–	–	0.14%	100
2022 Q1	$311K	Hold	5,000	–	–	0.2%	89
2021 Q4	$353K	Hold	5,000	–	–	0.21%	83
2021 Q3	$349K	Hold	5,000	–	–	0.22%	90
2021 Q2	$417K	Buy	+5,000	New	+$354K	0.25%	85
2016 Q3	$364K	Hold	13,410	–	–	0.39%	76
2016 Q2	$383K	Sell	13,410 -185	-1%	-$5.88K	0.42%	75
2016 Q1	$410K	Hold	13,595	–	–	0.45%	72
2015 Q4	$471K	Buy	13,595 +600	+5%	+$20.5K	0.48%	71
2015 Q3	$492K	Hold	12,995	–	–	0.52%	70
2015 Q2	$741K	Sell	12,995 -28,510	-69%	-$1.62M	0.7%	59
2015 Q1	$2.42M	Sell	41,505 -1,690	-4%	-$90.8K	2.15%	5
2014 Q4	$2.45M	Hold	43,195	–	–	2.21%	5
2014 Q3	$1.77M	Sell	43,195 -280	-0.6%	-$12.9K	1.63%	11
2014 Q2	$1.98M	Sell	43,475 -67,896	-61%	-$2.85M	1.75%	12
2014 Q1	$5.26M	Buy	111,371 +55,370	+99%	+$2.52M	2.52%	3
2013 Q4	$2.63M	Buy	+56,001	New	+$2.45M	2.55%	5

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Penbrook Management's HBIO Position: Q3 2022 in Review

Penbrook Management sold out of Harvard Bioscience (HBIO) in Q3 2022, closing a stake of 5,000 shares — an estimated $180K sold.

Penbrook Management first reported a position in HBIO in Q4 2013 and held it in 17 quarters. The position peaked at $5.26M in Q1 2014. 79 funds tracked by Wall St. Rank hold HBIO as of Q3 2022.

Penbrook Management reported no remaining Harvard Bioscience position as of Q3 2022 after selling out during the quarter.
Penbrook Management sold 5,000 Harvard Bioscience shares in Q3 2022, an estimated $180K.
Penbrook Management first reported a position in Harvard Bioscience in Q4 2013 and held it in 17 quarters.
Penbrook Management's Harvard Bioscience position peaked at $5.26M in Q1 2014.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2022.

Based on Penbrook Management's 13F filing for Q3 2022, filed 31 Oct 2022.